数字兄弟姐妹透露了阿尔茨海默病的独特分子和临床亚型,通过omics驱动的分析
Bethany Bengs1, Russell H Swerdlow2, Jefferey Burns2
1Department of Biostatistics & Data Science, The University of Kansas Medical Center, Kansas City, KS, USA.
Journal of the neurological sciences
|February 16, 2026
概括
研究人员通过合并患者数据,在阿尔茨海默病 (AD) 中确定了"数字兄弟姐妹". 这种分层细化了子组的表征,并为神经退行性疾病提供了精确医学.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 计算生物学 计算生物学
背景情况:
- 阿尔茨海默病 (AD) 呈现出显著的异质性,具有挑战性的个性化治疗和预后.
- 数据驱动的方法对于确定患者相似性和精准医学中AD的分子特征至关重要.
研究的目的:
- 应用多重学习来融合来自AD患者的多种omic,人口统计和临床数据.
- 通过使用隐性空间表示来识别具有相似分子和临床配置文件的患者子组.
- 揭示推动AD异质性的分子机制,并为个性化治疗策略提供信息.
主要方法:
- 利用多种学习技术,整合了来自438名阿尔茨海默病患者的蛋白质学,人口学和临床数据集.
- 在学习的潜伏空间中使用聚类和分层来识别"数字兄弟姐妹".
- 对已识别的患者子组进行路径丰富和网络分析.
主要成果:
- 成功识别了"数字兄弟姐妹" - - 具有密切相关的分子和临床特征的患者.
- 揭示了与年龄,酒精使用和并发症等临床特征相关的独特途径丰富.
- 提供了有关与AD异质性相关的蛋白质相互作用网络的见解.
结论:
- 基于"数字兄弟姐妹"的分层提供了一个强大的方法来表征AD患者子组.
- 这种方法为开发结合纵向进展和干预结果的预测模型奠定了基础.
- 突出了数据驱动方法在阿尔茨海默病中推进精准医学的潜力.
更多相关视频
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
1.5K
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
12.3K
相关概念视频
Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Alzheimer's Disease: Treatment
1.0K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.0K
